Progression-free survival was significantly longer with crizotinib than with chemotherapy ( median , @ months vs. @ months ; hazard ratio for progression or death with crizotinib , @ ; @ % confidence interval -LSB- CI -RSB- , @ to @ ; P < @ ) .